Zydus Cadila gets final nod from USFDA for Sevelamer Carbonate Tablets

13 Aug 2020 Evaluate

Zydus Cadila has received final approval from the US Food & Drug Administration (USFDA) to market Sevelamer Carbonate Tablets (US RLD - Renvela Tablets) in the strength of 800 mg.

The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

929.05 6.60 (0.72%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×